Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MINIZIDE vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Prazosin is a selective alpha-1 adrenergic antagonist that inhibits vascular smooth muscle contraction, reducing peripheral vascular resistance and blood pressure. Polythiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing sodium and water excretion, and reducing intravascular volume.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
1-2 capsules orally twice daily; each capsule contains prazosin 0.5 mg and polythiazide 0.5 mg. Titrate based on blood pressure response.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
2-3 hours (prazosin component); prolonged in heart failure or renal impairment
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Prazosin is extensively metabolized in the liver via O-demethylation and conjugation, primarily by CYP3A4. Polythiazide is not extensively metabolized; it is excreted unchanged in the urine.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Renal: 90% (unchanged drug and metabolites); biliary/fecal: <10%
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
97% (prazosin bound to alpha-1 acid glycoprotein and albumin)
~20% bound to albumin; minimal binding to other plasma proteins.
0.6 L/kg (prazosin); reflects extensive tissue distribution
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Oral: 50-70% (prazosin); first-pass metabolism reduces systemic availability
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-60 m L/min: use with caution, reduce dose by 50%, monitor electrolytes. No adjustment for GFR >60 m L/min.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh A: no adjustment necessary. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use due to risk of hepatic encephalopathy.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not recommended for pediatric use due to lack of safety and efficacy data.
Not recommended; inadequate safety data.
Initiate therapy at the lower end of the dosing range (1 capsule daily) due to increased sensitivity to orthostatic hypotension and electrolyte disturbances. Titrate slowly.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
None.
None
First-dose syncope (orthostatic hypotension) can occur, especially with initial use or dose escalation,Sodium and water depletion may occur with thiazide, leading to hypokalemia, hyponatremia, and hypomagnesemia,May exacerbate renal impairment; monitor renal function,May increase serum uric acid and precipitate gout,May cause hypersensitivity reactions, including anaphylaxis and angioedema
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Anuria,Hypersensitivity to prazosin, polythiazide, or sulfonamide-derived drugs (thiazides),Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid high-potassium foods (e.g., bananas, oranges) if potassium-sparing diuretics or supplements are used; hydrochlorothiazide can cause hypokalemia so potassium-rich foods may be recommended. Grapefruit juice may increase prazosin levels; avoid.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
Prazosin-polythiazide combination. First trimester: Risk category C; limited human data. Second and third trimesters: potential fetal/neonatal effects include hypotension, electrolyte imbalance, and decreased placental perfusion. Avoid use unless clearly needed.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Prazosin: low levels in breast milk; M/P ratio 0.75-1.0. Polythiazide: may suppress lactation; M/P ratio unknown. Use caution, monitor infant for diuretic effects or hypotension.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
Increased plasma volume and renal clearance may reduce drug levels; consider monitoring therapeutic effect and adjust dose accordingly. No fixed dosing guidelines; cautious titration recommended.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
MINIZIDE (prazosin/hydrochlorothiazide) is a fixed-dose combination for hypertension. Prazosin causes first-dose syncope; start with 1 mg at bedtime. Hydrochlorothiazide may cause hypokalemia; monitor potassium. Use cautiously in patients with history of angioedema from ACE inhibitors as prazosin may also cause angioedema.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take first dose at bedtime to avoid fainting.,Rise slowly from sitting or lying to prevent dizziness.,Avoid alcohol as it may worsen side effects.,Report episodes of fainting or rapid heartbeat.,Do not stop abruptly; may cause rebound hypertension.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MINIZIDE vs ALDORIL D50, answered by our medical review team.
MINIZIDE is a Antihypertensive Combination that works by Prazosin is a selective alpha-1 adrenergic antagonist that inhibits vascular smooth muscle contraction, reducing peripheral vascular resistance and blood pressure. Polythiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing sodium and water excretion, and reducing intravascular volume.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MINIZIDE and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MINIZIDE is: 1-2 capsules orally twice daily; each capsule contains prazosin 0.5 mg and polythiazide 0.5 mg. Titrate based on blood pressure response.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MINIZIDE and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MINIZIDE is classified as Category C. Prazosin-polythiazide combination. First trimester: Risk category C; limited human data. Second and third trimesters: potential fetal/neonatal effects include hypotension, electrol. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.